Novavax (NASDAQ:NVAX) Stock Price Crosses Above Fifty Day Moving Average – Here’s What Happened

Novavax, Inc. (NASDAQ:NVAX) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $10.43 and traded as high as $10.62. Novavax shares last traded at $10.47, with a volume of 2,790,195 shares.

Key Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Sanofi triggered a $125 million milestone payment. Sanofi’s initiation of a European Phase 3 trial for an influenza-COVID-19 combination vaccine—after the fifth patient was dosed—earned Novavax the payment under their collaboration and license agreement. The trial uses Novavax’s Nuvaxovid COVID-19 vaccine with Sanofi’s high-dose flu vaccine. The cash payment is meaningful relative to Novavax’s roughly $1.66 billion market value and supports near-term liquidity. Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
• Positive Sentiment: The Sanofi collaboration retains additional upside through potential future milestones and royalties. A successful combination vaccine could give Novavax exposure to global flu and COVID-19 markets valued at more than $10 billion combined, although commercialization remains dependent on trial results and regulatory approvals. Novavax Earns $125 Million Milestone Payment From Sanofi’s Phase 3 Vaccine Trial in Europe
• Neutral Sentiment: Brokerages have a consensus price target of $12.33, above the recent trading level, but the target reflects mixed analyst views and is not a guarantee of further gains. Novavax Stock Has Consensus Target Price of $12.33 According to Brokerages
• Neutral Sentiment: Novavax will report third-quarter 2026 results before the market opens on November 5, followed by a management webcast. The event could provide updates on vaccine demand, cash flow and the Sanofi partnership. Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
• Negative Sentiment: Analysts and Zacks warn that Novavax may report another negative quarter and lacks the favorable earnings and estimate-revision trends typically associated with a likely earnings beat. That concern may be limiting the stock’s response to the Sanofi payment. Novavax May Report Negative Earnings

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Zacks Research downgraded Novavax from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Citigroup reaffirmed a “sell” rating and set a $8.00 price objective (up from $7.00) on shares of Novavax in a research report on Thursday, October 15th. Wall Street Zen upgraded Novavax from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Novavax in a report on Tuesday, August 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Novavax in a report on Tuesday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $12.33.

Novavax Price Performance

The stock has a market capitalization of $1.66 billion, a PE ratio of -6.63 and a beta of 2.44. The stock has a 50 day moving average of $10.46 and a two-hundred day moving average of $9.30.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The business had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $52.51 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. The company’s revenue was down 76.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. As a group, research analysts predict that Novavax, Inc. will post -0.50 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novavax

Several hedge funds have recently made changes to their positions in NVAX. TSP Capital Management Group LLC lifted its holdings in Novavax by 0.9% in the third quarter. TSP Capital Management Group LLC now owns 1,432,365 shares of the biopharmaceutical company’s stock worth $15,484,000 after acquiring an additional 13,000 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Novavax during the second quarter valued at approximately $8,004,000. Edgestream Partners L.P. bought a new position in shares of Novavax during the first quarter valued at approximately $4,234,000. Renaissance Technologies LLC bought a new position in shares of Novavax during the first quarter valued at approximately $4,049,000. Finally, First Trust Advisors LP grew its holdings in shares of Novavax by 37.7% during the first quarter. First Trust Advisors LP now owns 409,328 shares of the biopharmaceutical company’s stock valued at $3,332,000 after purchasing an additional 112,009 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.